A second cervical cancer vaccine may soon be available.
Drug-maker Glaxo-Smith-Kline is asking the food and drug administration to approve its cervical cancer vaccine called "Cervarix." The company just submitted final data on a phase iii clinical study involving more than 18,000 teen girls and women.
Like Merck's Gardasil already on the market, Cervarix works by protecting against the human papillomavirus, which is a cause of cervical cancer.
Cervarix is currently used in more than 90 countries. It could be approved by the FDA within about 6 months.